Last updated: 2026-09-16 11:41:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Editas Medicine, Inc. (EDIT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.66, with a market capitalisation of $420.81M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.66 to $4.54. This page covers its latest market performance, valuation, price trends and company information.
$420.81M | |
$2.63 | |
$99.95 | |
$0.91 | |
$2.63 | |
1.12K | |
2.37M | |
-- | |
$4.54 | |
$1.66 | |
-- | |
-- |
Editas Medicine, Inc. (EDIT) is trading at $2.66 in pre-market trading as of 2026-09-16 11:28:00, up 0.95% ($0.02) from the previous close of $2.63
Pre-market trading shows how investors are pricing EDIT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Editas Medicine, Inc. (EDIT) moved from $3.23 to $2.66, representing a decline of 17.80% ($0.58).
The stock traded between $2.59 and $3.23 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.15 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 34.6%
EDIT is currently trading at $2.66, placing it 34.6% of the way from its 52-week low of $1.66 to its 52-week high of $4.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Editas Medicine, Inc. (EDIT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.